Belfast antibody discovery company Fusion Antibodies has said it expects “continued growth in financial performance” after reporting a jump in revenues.
The company said turnover climbed by 14% to £4.8 million for the 12 months to the end of March 2022, with growth recorded in all geographical regions.
In a trading update to the Alternative Investment Market on the London Stock Exchange, Fusion Antibodies said it had managed to overcome the challenges presented by the Covid-19 pandemic and has found increasing demand for its services.
